Dizal Pharmaceutical(SH:688192) Sou Hu Cai Jing·2026-01-12 18:40Trading Information - On January 12, 2026, Dize Pharmaceutical (688192) closed at 66.94 yuan, with a slight increase of 0.22% and a turnover rate of 0.76%. The trading volume was 34,500 shares, with a total transaction value of 231 million yuan [1] - On the same day, the net inflow of main funds was 4.5775 million yuan, accounting for 1.98% of the total transaction value. The net inflow of speculative funds was 7.0625 million yuan, accounting for 3.05% of the total transaction value. Retail investors had a net outflow of 11.6399 million yuan, accounting for 5.03% of the total transaction value [1][4] Performance Forecast - Dize Pharmaceutical has released a performance forecast, estimating a total revenue of approximately 800 million yuan for the year 2025. The company anticipates a net loss of about 850 million yuan after deducting non-recurring items and a net loss attributable to shareholders of approximately 770 million yuan [2][4] Company Announcements - Dize Pharmaceutical expects to achieve an annual revenue of around 800 million yuan in 2025, representing a year-on-year increase of 122.28%. The R&D expenses are projected to be around 860 million yuan, reflecting an 18.84% year-on-year increase. The net loss attributable to the parent company is estimated to be around 770 million yuan, which is a reduction in loss of 8.98% year-on-year. The losses are primarily due to sustained high R&D investments [3] - Two products, Shuwozhe and Gaoruizhe, have been included in the national medical insurance catalog. Additionally, Shuwozhe has received FDA approval and has been included in the NCCN guidelines. The company has also reported multiple clinical progress updates for its pipeline products and has received FDA fast track designation [3][4]